Abstract
Immunotherapy Ingestion of gluten-containing food triggers the gastrointestinal symptoms of celiac disease in patients with CD4+ T cells specific for deamidated gluten peptides presented by cells. Frick et al. used phage display technology to screen for T cell receptor (TCR)–like antibodies specific for an immunodominant gluten peptide bound by the protein HLA-DQ2.5. Antibody engineering optimized affinity and binding stability, yielding an improved TCR-like antibody that structurally mimicked the TCR interface with gluten peptide–protein complexes. These TCR-like antibodies blocked the activation and proliferation of gluten-responsive human CD4+ T cells both in vitro and in DQ2.5-transgenic mice. TCR-like antibodies that block immunodominant epitope recognition have potential as personalized treatments for blunting gluten-activated T cell responses without compromising the effector functions provided by other T cells. Sci. Immunol. 6 , eabg4925 (2021).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
